Correspondence
Joanna Parkinson, PhD
Clinical Pharmacology and Quantitative Pharmacology,
Clinical Pharmacology and Safety Sciences, R&D,
AstraZeneca,
Pepparedsleden 1
431 50 Mölndal, Sweden
Email: joanna.parkinson@astrazeneca.com
Principal investigator statement: This was a pure population
pharmacokinetic (PK) analysis of one Phase 2 and two Phase 3
international studies. Consequently, none of the principal investigators
have contributed to the sample collection design, PK analysis plan, data
analysis and manuscript preparation. Therefore, principal investigators
have not been included as co-authors in this manuscript.
Running head: Similar dapagliflozin PK in T1DM & T2DM
Keywords: dapagliflozin, diabetes, pharmacokinetics